Clik here to view.
Ranok Therapeutics Expands Clinical Testing of CHAMP® BRD4 Protein Degrader...
BOSTON & HANGZHOU, China Ranok Therapeutics, a clinical-stage biopharmaceutical company that is developing a novel approach to targeted protein degradation for the treatment of cancers, today...
View ArticleClik here to view.
InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in...
BEIJING InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the...
View ArticleClik here to view.
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating...
OSAKA, Japan & CAMBRIDGE, Mass. Takeda (TSE:4502/NYSE:TAK) today announced positive topline results from a Phase 2, randomized, double-blind, placebo-controlled study evaluating the safety,...
View ArticleClik here to view.
First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic...
SEATTLE & BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. The Max Foundation (Max), a global nonprofit organization dedicated to accelerating health equity by delivering medication,...
View ArticleClik here to view.
Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate...
SHANGHAI & CAMBRIDGE, Mass. Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will present findings from preclinical studies highlighting the therapeutic potential of ZL-1310,...
View ArticleClik here to view.
マックス財団、ベイジーン、ベイジーン財団の協力により、低・中所得国の慢性リンパ性白血病患者にBRUKINSA®を初回投与
SEATTLE & BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. （ビジネスワイヤ） —...
View ArticleClik here to view.
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or...
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration...
View ArticleClik here to view.
BeiGene、化学療法後の進行性または転移性食道扁平上皮癌の治療のためのTEVIMBRA®のFDA承認取得
スイス・バーゼル、北京、マサチューセッツ・ケンブリッジ （ビジネスワイヤ） — グローバルな腫瘍学企業であるBeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235)...
View ArticleClik here to view.
Inocras Inc. Unveils Rebranding of Genome Insight
SAN DIEGO Inocras, formerly known as Genome Insight, announced today its rebranding initiative to reflect its commitment to innovation and user-centric healthcare solutions. The AI-driven whole...
View ArticleClik here to view.
GRAIL Announces Novel Risk Classification Test to Be Used in Lung Cancer Study
MENLO PARK, Calif. & CAMBRIDGE, England GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, announced today that participants from Japan, via a...
View ArticleClik here to view.
Crown Bioscienceが3年連続でT+ Employer®に認定される
米国サンディエゴ （ビジネスワイヤ） — 世界的な医薬品開発業務受託機関(CRO)であり、JSRライフサイエンスの傘下企業でもあるCrown Bioscienceは、2020年にこのT+ Employer®認証が創設されて以来、毎年、ヘルスケアに対する優良企業として認定され、世界のヘルスケア分野におけるトップランナーとしての地位を確固たるものにしています。...
View ArticleClik here to view.
冠科生物连续三年荣膺T+ Employer® 卓越雇主
圣地亚哥，美国 (美国商业资讯)– 冠科生物，JSR Life Sciences旗下子公司，是一家全球合同研究组织（CRO）。自2020年T+ Employer®卓越雇主奖项设立后，冠科生物每年都荣获该奖项，巩固了其在全球医疗大健康领域的领先地位。 这个由中国国家卫生健康委人才交流服务中心和医趋势联合颁发的奖项，彰显了该公司贯彻始终地致力于培养以包容性、创新和卓越客户服务为标志的企业文化。...
View ArticleClik here to view.
Dr. Reddy’s Laboratories launches Versavo® (bevacizumab) in the UK
HYDERABAD, India Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; hereafter referred to as “Dr. Reddy’s”), a global pharmaceutical company, announced the launch...
View ArticleClik here to view.
Takeda Announces U.S. FDA Approval of Supplemental New Drug Application...
OSAKA, Japan & CAMBRIDGE, Mass. Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ICLUSIG®...
View ArticleClik here to view.
ImpriMed to Present Innovative Research at 2024 World Veterinary Cancer Congress
MOUNTAIN VIEW, Calif. WVCC – ImpriMed, a leading precision medicine startup focused on leveraging artificial intelligence to improve cancer treatment, today announced the company’s participation at...
View ArticleClik here to view.
Charles River Announces Extension of Gene Therapy Manufacturing Alliance with...
WILMINGTON, Mass. Charles River Laboratories International, Inc. (NYSE: CRL) and National University of Singapore’s (NUS) Yong Loo Lin School of Medicine (NUS Medicine), a leading medical education...
View ArticleClik here to view.
武田薬品、Ph+ ALLの初発成人患者に対するアイクルシグ®（ポナチニブ）の医薬品承認事項変更申請（sNDA）について、FDAからの承認取得を発表
大阪&米マサチューセッツ州ケンブリッジ （ビジネスワイヤ） — 武田薬品（TSE:4502/NYSE:TAK）は、フィラデルフィア染色体陽性急性リンパ芽球性白血病（Ph+...
View ArticleClik here to view.
Takeda宣布美国FDA批准ICLUSIG ®(帕纳替尼)的补充性新药申请(sNDA)，用于治疗新近诊断为Ph+ ALL的成年患者
日本大阪和美国麻省坎布里奇 (美国商业资讯)– Takeda (...
View ArticleClik here to view.
Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific...
BEIJING Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with...
View ArticleClik here to view.
百奥赛图与ABL Bio达成合作，共同开发新型双抗ADC药物
中国北京 (美国商业资讯)– 百奥赛图（北京）医药科技股份有限公司（“百奥赛图”，股票代码02315.HK），一家创新技术驱动抗体类新药研发的国际性生物技术公司今日宣布与ABL Bio Inc.（“ABL”，KOSDAQ：298380），一家处于临床阶段开发新型肿瘤和中枢神经系统疾病疗法的韩国生物技术公司达成合作，共同开发新型双特异性抗体偶联药物（双抗ADC）。...
View Article